These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 26563355)

  • 41. NTRK fusion-positive colorectal cancer in Japanese population.
    Yonemaru J; Hashimoto T; Takayanagi D; Naka T; Yatabe Y; Kanemitsu Y; Shiraishi K; Sekine S
    Pathol Int; 2021 May; 71(5):355-359. PubMed ID: 33631044
    [TBL] [Abstract][Full Text] [Related]  

  • 42. TrkA overexpression in non-tumorigenic human breast cell lines confers oncogenic and metastatic properties.
    Kyker-Snowman K; Hughes RM; Yankaskas CL; Cravero K; Karthikeyan S; Button B; Waters I; Rosen DM; Dennison L; Hunter N; Donaldson J; Christenson ES; Konstantopoulos K; Hurley PJ; Croessmann S; Park BH
    Breast Cancer Res Treat; 2020 Feb; 179(3):631-642. PubMed ID: 31823098
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Generalized eruptive histiocytosis associated with a novel fusion in LMNA-NTRK1.
    Pinney SS; Jahan-Tigh RR; Chon S
    Dermatol Online J; 2016 Aug; 22(8):. PubMed ID: 27617936
    [TBL] [Abstract][Full Text] [Related]  

  • 44. NTRK fusion in Japanese colorectal adenocarcinomas.
    Yamashiro Y; Kurihara T; Hayashi T; Suehara Y; Yao T; Kato S; Saito T
    Sci Rep; 2021 Mar; 11(1):5635. PubMed ID: 33707574
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A novel in-cell ELISA method for screening of compounds inhibiting TRKA phosphorylation, using KM12 cell line harboring TRKA rearrangement.
    Pandre MK; Shaik S; Satya Pratap VVV; Yadlapalli P; Yanamandra M; Mitra S
    Anal Biochem; 2018 Mar; 545():78-83. PubMed ID: 29360440
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification of differentially expressed genes in papillary thyroid carcinomas with and without rearrangements of the tyrosine kinase receptors RET and/or NTRK1.
    Musholt TJ; Brehm C; Hanack J; von Wasielewski R; Musholt PB
    J Surg Res; 2006 Mar; 131(1):15-25. PubMed ID: 16256137
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rearrangements of NTRK1 gene in papillary thyroid carcinoma.
    Greco A; Miranda C; Pierotti MA
    Mol Cell Endocrinol; 2010 May; 321(1):44-9. PubMed ID: 19883730
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Oncogenic rearrangements of the NTRK1/NGF receptor.
    Pierotti MA; Greco A
    Cancer Lett; 2006 Jan; 232(1):90-8. PubMed ID: 16242838
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population.
    Brzeziańska E; Karbownik M; Migdalska-Sek M; Pastuszak-Lewandoska D; Włoch J; Lewiński A
    Mutat Res; 2006 Jul; 599(1-2):26-35. PubMed ID: 16483615
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Somatic chromosomal engineering identifies BCAN-NTRK1 as a potent glioma driver and therapeutic target.
    Cook PJ; Thomas R; Kannan R; de Leon ES; Drilon A; Rosenblum MK; Scaltriti M; Benezra R; Ventura A
    Nat Commun; 2017 Jul; 8():15987. PubMed ID: 28695888
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Identifying patients with NTRK fusion cancer.
    Solomon JP; Benayed R; Hechtman JF; Ladanyi M
    Ann Oncol; 2019 Nov; 30(Suppl_8):viii16-viii22. PubMed ID: 31738428
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rearrangements of NTRK1 oncogene in papillary thyroid carcinoma.
    Brzeziańska E; Pastuszak-Lewandoska D; Lewiński A
    Neuro Endocrinol Lett; 2007 Jun; 28(3):221-9. PubMed ID: 17627253
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibition of MEK1/2 Forestalls the Onset of Acquired Resistance to Entrectinib in Multiple Models of NTRK1-Driven Cancer.
    Vaishnavi A; Scherzer MT; Kinsey CG; Parkman GL; Truong A; Ghazi P; Schuman S; Battistone B; Garrido-Laguna I; McMahon M
    Cell Rep; 2020 Aug; 32(5):107994. PubMed ID: 32755586
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Entrectinib Induces Apoptosis and Inhibits the Epithelial-Mesenchymal Transition in Gastric Cancer with NTRK Overexpression.
    Sohn SH; Sul HJ; Kim BJ; Kim HS; Zang DY
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008821
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Emerging Targeted Therapy for Tumors with
    Kheder ES; Hong DS
    Clin Cancer Res; 2018 Dec; 24(23):5807-5814. PubMed ID: 29986850
    [TBL] [Abstract][Full Text] [Related]  

  • 56. TRK inhibitors in TRK fusion-positive cancers.
    Drilon A
    Ann Oncol; 2019 Nov; 30 Suppl 8():viii23-viii30. PubMed ID: 32223935
    [TBL] [Abstract][Full Text] [Related]  

  • 57. TRKA expression and
    Mauri G; Valtorta E; Cerea G; Amatu A; Schirru M; Marrapese G; Fiorillo V; Recchimuzzo P; Cavenago IS; Bonazzina EF; Motta V; Lauricella C; Veronese S; Tosi F; Maiolani M; Rospo G; Truini M; Bonoldi E; Christiansen J; Potts SJ; Siena S; Sartore-Bianchi A
    J Clin Pathol; 2018 Oct; 71(10):926-931. PubMed ID: 29802225
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Characterization of the NTRK1 genomic region involved in chromosomal rearrangements generating TRK oncogenes.
    Greco A; Mariani C; Miranda C; Pagliardini S; Pierotti MA
    Genomics; 1993 Nov; 18(2):397-400. PubMed ID: 8288244
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A novel group of spindle cell tumors defined by S100 and CD34 co-expression shows recurrent fusions involving RAF1, BRAF, and NTRK1/2 genes.
    Suurmeijer AJH; Dickson BC; Swanson D; Zhang L; Sung YS; Cotzia P; Fletcher CDM; Antonescu CR
    Genes Chromosomes Cancer; 2018 Dec; 57(12):611-621. PubMed ID: 30276917
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A rare case of recurrent ovarian cancer with
    Endo Y; Watanabe T; Saito M; Saito K; Suzuki R; Sano H; Natori Y; Sasaki E; Ueda M; Kamo N; Furukawa S; Soeda S; Kono K; Saji S; Fujimori K
    Mol Clin Oncol; 2022 Apr; 16(4):90. PubMed ID: 35251641
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.